Isolation, Identification and Chemical Modification of Bufadienolides from Bufo melanostictus Schneider and Their Cytotoxic Activities against Prostate Cancer Cells.
Qingmei YeRong LinZeping ChenJuan LiCai-Juan ZhengPublished in: Molecules (Basel, Switzerland) (2024)
The traditional Chinese medicine toad venom ( Venenum bufonis ) has been extensively used to treat various diseases, including cancers, in China and other Southeast Asian countries. The major constituents of toad venom, e.g., bufadienolides and alkaloids, exhibit broad-spectrum pharmacological effects in cancers. Herein, two new bufadienolides ( 1 and 2 ), along with eleven known compounds ( 3 - 13 ) were successfully isolated from Bufo melanostictus Schneider. Their structures were elucidated by extensive spectroscopic data and X-ray diffraction analysis. Furthermore, four lactam derivatives were synthesized through the transformation of bufadienolides lactones. The inhibitory effects of these compounds against human prostate cancer cell lines PC-3 and DU145 were evaluated. The outcomes indicated a notable trend, with a substantial subset displaying nanomolar range IC 50 values against PC-3 and DU145 cells, underscoring their pronounced cytotoxicity. Moreover, a noteworthy distinction surfaces, wherein lactones consistently outperformed their lactam counterparts, further validating their heightened potency for the treatment of prostate cancer. This study contributes significant preclinical evidence substantiating the therapeutic viability of bufadienolides and toad venom as intervention strategies for prostate cancer.
Keyphrases
- prostate cancer
- radical prostatectomy
- high resolution
- randomized controlled trial
- induced apoptosis
- electronic health record
- gram negative
- escherichia coli
- computed tomography
- mesenchymal stem cells
- stem cells
- staphylococcus aureus
- signaling pathway
- cell proliferation
- oxidative stress
- cystic fibrosis
- insulin resistance
- adipose tissue
- deep learning
- biofilm formation
- glycemic control
- artificial intelligence
- dual energy
- contrast enhanced
- childhood cancer